National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ravulizumab (Ultomiris®) is indicated for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):

– in patients with haemolysis with clinical symptom(s) indicative of high disease activity

– in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.

NCPE Assessment Process Complete
Rapid Review commissioned 04/12/2019

 

Rapid Review completed 02/03/2020
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ravulizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
Full pharmacoeconomic assessment commissioned by the HSE 04/03/2020
Current status HTA commissioned by the HSE